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Background: Molecular targeted therapy has emerged as a promising treatment of Hepatocellular carcinoma
(HCC). One potential target is the Src family Kinase (SFK). C-Src, a non-receptor tyrosine kinase is a critical link of
multiple signal pathways that regulate proliferation, invasion, survival, metastasis, and angiogenesis. In this study, we
evaluated the effects of a novel SFK inhibitor, dasatinib (BMS-354825), on SFK/FAK/p130CAS, PI3K/PTEN/Akt/mTOR,
Ras/Raf/MAPK and Stats pathways in 9 HCC cell lines.
Methods: Growth inhibition was assessed by MTS assay. EGFR, Src and downstream proteins FAK, Akt, MAPK42/44,
Stat3 expressions were measured by western blot. Cell adhesion, migration and invasion were performed with and
without dasatinib treatment.
Results: The IC50 of 9 cell lines ranged from 0.7 μM~ 14.2 μM. In general the growth inhibition by dasatinib was
related to total Src (t-Src) and the ratio of activated Src (p-Src) to t-Src. There was good correlation of the sensitivity to
dasatinib and the inhibition level of p-Src, p-FAK576/577 and p-Akt. No inhibition was found on Stat3 and MAPK42/44
in all cell lines. The inhibition of cell adhesion, migration and invasion were correlated with p-FAK inhibition.
Conclusion: Dasatinib inhibits the proliferation, adhesion, migration and invasion of HCC cells in vitro via inhibiting of
Src tyrosine kinase and affecting SFK/FAK and PI3K/PTEN/Akt, but not Ras/Raf/MEK/ERK and JAK/Stat pathways.
T-Src and p-Src/t-Src may be useful biomarkers to select HCC patients for dasatinib treatment.
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Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies worldwide accounting for 500,000 ~
600,000 deaths per year [1]. The major obstacles in the
treatment of HCC are low resectable and high recurrence
rates in patients with early disease and a poor response to
chemotherapy and radiation in advanced stage disease
[2,3]. In addition, a majority of HCC patients also have
liver cirrhosis with poor liver functions and performance
status, thus limiting their ability to receive treatment. In
fact, the existing conventional chemotherapeutics are
non-selective cytotoxic drugs with systemic side effects
and no proven survival benefit. Therefore, there is often* Correspondence: alexchang@imc.jhmi.edu
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[1,4]. In some series, up to 50% of patients with newly di-
agnosed HCC were only given supportive or palliative
therapy. There is an urgent need to develop novel treat-
ments for advanced HCC.
Targeted therapies that specifically inhibit pivotal
molecular abnormalities have emerged as a promising ap-
proach for various cancers, including HCC [5]. Sorafenib,
a dual inhibitor of Raf Kinase and VEGFR, is the only ap-
proved agent for treating advanced HCC. Sorafenib when
compared to placebo prolongs the survival modestly by 2
to 3 months. Therefore, more efforts are necessary in the
identification of new molecular targets to improve treat-
ment further. One potential target is found in the Src fam-
ily Kinase (SFK). C-Src, a non-receptor tyrosine kinase,
has been found to be a critical component of multiple sig-
naling pathways that regulate proliferation, invasion,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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these activities, C-Src inter-acts with numerous cellular
factors, including integrins, growth factor receptors, G-
protein coupled receptors and cytokine receptors to initi-
ate their downstream signaling cascades [8]. C-Src can
cooperate with receptor kinases to signal through down-
stream molecules, such as PI3K/PTEN/Akt, Ras/Raf/
Mek1/2/Erk1/2 and Stats [9-11]. C-Src also interacts with
focal adhesion kinase (FAK), which plays an important
role in integrin signaling and is highly expressed in many
tumor cells, including HCC [12]. Tyrosyl phosphorylation
of FAK interacts with multiple cellular proteins to modu-
late cell adhesion, migration and invasion [11].
Dasatinab (BMS-354825), a potent oral tyrosine Kinase
inhibitor against the Src family Kinases, BCR-ABL, plate-
let derived growth factor receptor and c-Kit has demon-
strated multiple effects on solid tumors and has been
approved for use in patients with chronic myelogenous
leukemia refractory or intolerant to imatinib [13] and in
patients with Philadelphia chromosome-positive acute
lymphoblastic leukemia [14]. Although there are active
research studies evaluating the molecular mechanisms of
dasatinib on human solid tumor cells such as prostate
cancer, head and neck squamous cell carcinoma, non-
small cell lung cancer, breast cancer, but the true regula-
tory mechanisms are still not fully understood, especially
in HCC [15-21].
In this study, we hypothesize that dasatinib inhibits
HCC by modulating SFK/FAK/p130CAS, PI3K//PTEN/
Akt/mTOR, Ras/Raf/MAPK and/or Stats signaling path-
ways. The current investigation was undertaken to test
this hypothesis.
Methods
Cell lines and cell culture
Human hepatocellular carcinoma (HCC) cell lines,
HepG2, sk-Hep1, Hep3B were obtained from ATCC,
HLE, HLF, Huh-7, HT-17, PLC/PRF/6 and Li-7 were pro-
vided by Institute of Molecular and Cell Biology of
Singapore. All cell lines were cultured in Dulbecco’s Modi-
fied Eagle Medium [high Glucose (4.5 g/L), with Sodium
Pyruvate and L-glutamin] (PAA Laboratories Cell Culture
Products, Austria), containing 10% fatal bovine serum
(FBS) (Invitrogen, USA), 1% antibiotic with 100 IU/ml
Penicillin and 100ug/ml Streptomycin (Invitrogen, USA).
Incubation condition was set at 37°C in a humidified at-
mosphere of 95% air and 5% CO2. The culture medium
was changed 2 to 3 times a week and cells were passaged
using trypsin/EDTA (Invitrogen, USA).
Antibodies and reagents
Src rabbit monoclonal antibodies, β-actin, rabbit mo-
noclonal antibodies against the phosphor-Src(Tyr416),
phosphor-Akt(Ser473), phosphor-MAK42/44(Thr202/Tyr204), phosphor-Stat3(Tyr705), phosphor-FAK576/577
were from Cell Signaling Technologies, Canada. Poly-
clonal antibody to phosphor-FAK861 was purchased from
Invitrogen Corporation, Canada. Polyclonal goat anti-
rabbit immunoglobulins/HRP was from Dakocytomation,
Denmark. Recombinant human epidermal growth
factor was purchased from Invitrogen Corporation, USA.
Dasatinib was obtained from Bristol-Myers Squibb,
Princeton, USA.Growth inhibition assay
Dasatinib was diluted in pure DMSO to obtain a stock so-
lution of 10 mmol/L and stored in a −80°C freezer in
aliquots. CellTiter 96 Aqueous Non-Radioaction cell pro-
liferation Assay Kit (Promega Corporation, USA) was used
for growth inhibition assays. 4000–10,000 HCC cells from
9 cell lines were plated in 96-well flat-bottomed plates and
cultured for 24 hours (h). Cells were exposed to serially di-
luted dasatinib in DMEM with 1%FBS, for an additional
72 hours. 20 μl MTS/PMS solution was added into each
well containing 100 μl of the culture medium. Then, the
cells were incubated for 3 h at 37°C before measurement
of absorbance at 490 nm with a Benchmark Plus
microplate spectrophotometer (Bio-RAD, USA). Absorb-
ance values were expressed as a percentage of that for un-
treated cells, and the concentration of dasatinib resulting
in 50% growth inhibition (IC50) was calculated for each
cell line. As reported by us previously, we arbitrarily de-
fined the sensitive cell lines as having their IC50 ≤ 1uM
and the resistant cell lines IC50 ≥1uM [22].EGF stimulation and dasatinib treatment
Briefly, approximately 2 × 105 cells were seeded into 6-
well plates in serum containing medium. After 24 h cul-
ture, cells undertook serum starvation for additional 24 h
and then were exposed to 10 ng/ml EGF (Millipore, USA)
for PLC/PRF/6 cells and 200 ng/ml for sk-hep1 cells for
5 min, 10 min, 15 min, 30 min, 1 hour. Finally the cells
were harvested for western blotting analysis.
For dasatinib inhibition study, serum-starved cells were
treated with various concentrations of dasatinib for 24 h
prior to the addition of 20% FBS stimulation, and then
were collected for western blotting analysis. In order to
show that this treatment would not affect cellular viability,
we selected sk-Hep1 and Huh-7 as the representative ex-
amples of the sensitive and resistant cell lines to dasatinib
for the following experiment: 8000 cells were seeded into
96-well plate overnight, and then divided into 3 groups A,
B and C before dasatinib treatment. Group A was serum-
starved for 24 h, group B and C were incubated in culture
medium with 1% FBS and 10% FBS respectively. After an-
other 24 h dasatinib treatment MTS assay was used to de-
termine the cell viability.
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The cells were lysed for protein extraction using M-PER
mammalian protein extraction reagent with protease in-
hibitor and phosphatase inhibitor (Thermo scientific,
Pierce Biotechnology, USA). The total protein concentra-
tion was measured by BCA kit (Pierce Biotechnology,
USA). Isolated proteins (35 μg/lane) were separated by 8%
SDS-PAGE and transferred to a nitrocellulose membrane
by the iblot device (Invitrogen Corporation, CA). The
membranes were blocked with 5% BSA at room
temperature for 1 h and then subjected to immunoblots
using primary antibodies at 4°C overnight, followed by in-
cubation with secondary goat anti-rabbit IgG conjugated
to horseradish peroxidase for 1 h at room temperature.
Labeled protein was visualized by chemiluminescence
(Immobilon, Millipore Corperation, USA) and exposure
x-ray film (Kodak, USA), using β-actin expression as the
internal standard.Cell adhesion, migration and invasion assay
Cells were pretreated with dasatinib (1 μM) for 24 h after
being starved overnight at 37°C in a humidified incubator
containing 5% CO2. Cell adhesion assay was performed
using the cell adhesion assay kit (Chemicon International,
USA) by following the manufacturer instructions. Briefly,
96-well plates were coated with different Extracellular
Matrix (ECM) proteins. Pretreated cells were re-suspended
in assay buffer (Kit components) and seeded (1.5x105) in
each well. Plates were then incubated for 2 h at 37°C with
5% CO2. After removing the non-adherent cells and wash-
ing by assay buffer, cells were fixed and stained for 5 mi-
nutes, after washing 3–5 times with deionized water, the
cell-bonded stain was solubilized and quantified with an
ELASA plate reader (Benchmark Plus microplate spectro-
photometer, Bio-RAD, USA), at 560 nm.
Cell migration assays was done by using the cell migra-
tion assay kit (Chemicon International, USA). Briefly, in-
serts with an 8 μm pore size polycarbonate membrane
were utilized. 1.5 × 105 cells were pretreated with
dasatinib for 24 h and then seeded after washing off
dasatinib into the inserts. Same number of untreated cells
was used as control. All the inserts were put in the 24-
well plate which was considered as the lower chamber,
then DMEM with 10% FBS as the chemo- attractant was
supplied in each wells. The cells were allowed to incubate
at 37°C with 5% CO2 for 6 h and 16 h respectively. After
that, cells in the inner surface of the inserts were gently
removed. Cells that had migrated through the polycarbon-
ate membrane were incubated with cell stain solution
(kit components), then subsequently extracted and
detected on a standard microplate reader (Benchmark
Plus microplate spectrophotometer, Bio-RAD, USA), at
560 nm.Cell invasion assay was processed by using the cell inva-
sion assay kit (Chemicon International, USA). A 24-well
tissue culture plate with cell culture inserts which
contained an 8 μm pore size polycarbonate membrane
was used. 1.5 × 105 testing cells in serum free DMEM
were plated into ECM coated insert, then DMEM with
10% FBS was placed in the 24-well plate as chemo attrac-
tants. After 48 h incubation, the cells were removed from
the inner surface of the insert using a cotton-tipped swab.
The cells that invaded through the ECM layer and clung
to the bottom of the polycarbonate membrane were fixed
and stained. The number of migrating cells per insert was
captured microscopically.
Statistical analysis
All the experiments were repeated at least 3 times. Data
are reported as means ± SD. Correlation coefficient (r)
was calculated by the Pearson product–moment correl-
ation coefficient, and statistical significance (p-value) was
analyzed using t approximation. The expression level of
protein measured by western blot was analyzed by ImagJ
software, p-values were calculated using the Students
t-test.
Results
Growth inhibition by dasatinib in 9 HCC cell lines
The growth inhibition of each cell line was quantified by
IC50 of dasatinib which ranged from 0.7 μM~14.2 μM.
Dasatinib showed a dose-dependent inhibition in all 9
HCC cell lines, Sk-Sep 1, Li-7, and PLC/PRF/6 were most
sensitive with IC50 at or below 1 μM of dasatinib, while
Huh-7 was most resistant (Figure 1A).
Dasatinib inhibits Src activity and downstream signaling
The baseline levels of Src and activated Src (pY416-Src)
were measured in 9 HCC cell lines by western blotting
(Figure 1B and 1C). Except HT-17 and Huh-7 the rest of
the cell lines showed significant correlation between
growth inhibition by dasatinib (IC50) and the expression
level of total Src (t-Src) (p < 0.05, Figure 2A). The higher
the expression of t-Src, the more sensitive the HCC cell
lines were to dasatinib. The average expression percent of
p-Src in t-Src (p-Src/t-Src) for sensitive cell lines was sig-
nificantly lower than that of resistant cell lines except for
Huh-7 and HT-17 (p < 0.05). There was an extremely low
expression of p-Src at base line in Huh-7 cells. In the 6 re-
sistant cell lines we demonstrated that the specific activity
of Src (the ratio of p-Src/t-Src) was significantly associated
with the IC50 value of dasatinib. The lower the ratio of ac-
tivity of Src (p-Src/t-Src), the more resistant the HCC cell
lines to dasatinib (p = 0.001, Figure 2B). In 8 HCC cell
lines the high levels of Src expression were significantly
associated with low levels of EGFR expression (p = 0.05,













































































Figure 1 Baseline protein expression as well as IC50 of
dasatinib in HCC cell lines. A, 9 HCC cell lines were exposed to
the dedicated concentrations of dasatinib for 72 hours, and IC50 was
tested by MTS. Results represent the mean (± SD) of three
experiments. B and C, cell lysates were prepared from untreated
HCC cell lines and subjected to western blot analysis with antibodies
to p-Src416, t-Src, p-EGFR1068, t-EGFR and β-actin. D, the expression
ratio of p-Src416, P-EGFR1068, Src and EGFR to β-actin was
quantified by ImageJ software respectively. Results represented the


























































Figure 2 Correlation between the growth inhibition by
dasatinib and baseline protein expression. A. The correlation
between the growth inhibition by dasatinib and t-Src expression in
HCC cell lines. 7 out of 9 studied cell lines showed significant
correlation (r = −0.801, p = 0.03). B. The correlation between the IC50 of
dasatinib and the ratio of p-Src/t-Src in 6 dasatinib resistant HCC cell
lines. (r = −0.96, p = 0.001). C. The correlation between the expression
level of Src and EGFR in 8 out of 9 HCC cell lines(r = −0.62, p = 0.05). All
the studied protein expression were measured by western blot and
analyzed by ImageJ.
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pression level of phosphorylated EGFR (p-EGFR) was only
detected in 4 cell lines (PLC/PRF/6, Hep3B, HepG2 and
HT-17).HT-17 showed the highest specific activity of
EGFR (p-EGFR/t-EGFR) (Figure 1B and 1C). Figure 1D
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analyzed by software of ImageJ (Figure 1D). The cell via-
bility of group A, B and C did not show any significant dif-
ference by various concentration of dasatinib in sk-Hep1
and Huh-7 cells (Figure 3A and 3B, p > 0.05). Although
we showed serum affected the cell proliferation (Figure 3C
and 3D, p < 0.05), it couldn’t affect the response of HCC
cells to dasatinib.
The effects of dasatinib on Src and downstream targets
were detected by western blotting in dasatinib-treated
cells (Figure 4). The expression ratio of individual
phosphor-protein to β-actin was quantified by ImageJ
software (See Additional file 1). We analyzed the protein
inhibition level in HCC cells when treated with dasatinib
at the dosage of 1uM. In general, there was a significant
correlation between the IC50 of dasatinib and the inhib-
ition of p-Src (7/9, p < 0.05, Figure 5A), p-Akt (7/9,
p < 0.05, Figure 5B) and p-FAK576/577 (7/9, p < 0.01,
Figure 5C) by dasatinib. In all 3 sensitive cell lines, sk-
hep1, Li-7 and PLC/PRF/6, the sensitivity to dasatinib was
significantly correlated with p-Src and P-FAK576/577 in-
hibition by dasatinib. 5 out of 9 HCC cell lines including
all sensitive cell lines had a significant correlation between
p-Src inhibition and p-FAK576/577 inhibition by dasatinib
(p < 0.05, Figure 6A). P-Src inhibition and p-Akt inhibition
by dasatinib were also showed significant correlation in 5
HCC cell lines (p < 0.05, Figure 6B). We didn’t find any
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Figure 3 The comparison of cell viability with different treatment con
conditions as described in methods. Results represented the mean (±SD) o
(A) and Huh-7 (B) cells by dasatinib. Serum affected the cell concentration
dasatinib concentration.in all cell lines by dasatinib at the dosage of 1uM and
below (Figure 4).
Individually, sk-Hep1, the most sensitive to dasatinib
growth inhibition, showed only moderate inhibition of
p- Src, p-FAK576/577 and p-Akt by dasatinib at the dos-
age of 1uM. . Even though dasatinib completely inhibited
the expression of p-Src at 0.1uM in Li-7 cells, it only
moderately reduced the p-FAK576/577 activity without
inhibiting p-Akt (Figure 4); both sk-Hep1 and Li-7
expressed lower p-Src and p-Src/t-Src. It suggested that
dasatinib may affect other signal pathway and inhibiting
other protein kinase or growth factors to regulate cell
growth in these two cell lines. PLC/PRF/6 was the only
dasatinib sensitive cell line that co-overexpressed t-Src
and t-EGFR, higher baseline expression of p-Src and lower
p-Src/t-Src. In order to investigate whether dasatinib
would affect EGFR signaling pathway, the activity of EGFR
was tested too. The p-Src, p-FAK576/577, p-FAK861 and
p-Akt were significantly inhibited by dasatinib at 0.1uM,
p-EGFR1068 was inhibited at 10uM. No inhibition of t-
Src expression by dasatinib at all (Figures 4 and 7). It
appeared at lower concentration of dasatinib (0.01uM)
there was a slight increase of p-Src. The mechanism of
such difference is unknown. However, the ratio of p-Src/t-
Src of control vs dasatinib treatment (0.01um) did not
have any significant difference (p > 0.05).
Huh-7 was the least sensitive to dasatinib and very little
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dition. Sk-Hep1 and Huh-7 cells were treated under three different
f three experiments. There was no influence of cell survival of sk-Hep1











































Figure 4 The effect of dasatinib in cell signalling. Western blot
analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC
cell lines after 24 hours treatment of dasatinib. The cell lines were
arranged according to their IC50 to dasatinib. The top three were















































Figure 5 Correlation between the IC50 of dasatinib and the
inhibition on the activity of Src, Akt, FAK. The inhibition levels of
p-Src, p-Akt and p-FAK were measured when cells were treated with
dasatinib at the dosage of 1uM and analyzed by ImageJ software. To
analyze the correlation amongst the inhibition of different activated
proteins by dasatinib, the inhibition of activated protein is calculated
by the following formula, for example : pSrc Dð Þ=β−actin Dð ÞpSrc Cð Þ=β−actin Cð Þ, D for
dasatinib treatment, C for control. A, 7 out of 9 studied HCC cell
lines showed good correlation between IC50 and p-Src416 inhibition
(r = 0.745, p = 0.03). B, 7 out of 9 studied HCC cell lines showed
good correlation between IC50 and p-Akt473 inhibition (r = 0.732,
p = 0.03). C, 7 out of 9 studied HCC cell lines showed good
correlation between IC50 and P-FAK576/577 inhibition
(r = 0.838, p = 0.01).
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this cell line, dasatinib not only could not reduce p-FAK
at both 576/577 and 861 sites, but also increased the level
of them (Figure 4) suggesting Src dependant signaling
pathway is not crucial in the regulation of oncogenic pro-
cesses for Huh-7 cells.
HT-17 is one of the most resistant cell lines to dasatinib,
but is sensitive to gefitinib [22]. It showed highest activity
of EGFR at baseline. Even though dasatinib was able to
inhibit p-Src416 at the lower dosage (1uM), but did not
reduce p-Akt473 and P-MAPK42/44. These results indi-
cated that the cell growth of HT-17 was most likely de-
pendant on EGFR signal pathway.
Figure 8 showed that the response of phosphorylated
proteins to EGF stimulation varied in different cell lines.
P-Src can be activated by EGF (10 ng/ml) in PLC/PRF/6
(Figure 8A) but not in sk-Hep1 (Figure 8B). p-FAK 576/
577, 861 can be activated by EGF in both cell lines. It sug-











































Figure 6 Correlation of the expression level between p-FAK,
p-Akt and p-Src inhibition after dasatinib treatment. The
methods of measurement and calculation is the same as Figure 5.
A. 5 out of 9 HCC cell lines showed a good correlation between Src
and FAK inhibition by dasatinib (r = 0.843, p = 0.04). B. 5 out of 9
HCC cell lines showed a good correlation between p-Src and p-Akt
inhibition by dasatinib (r = 0.843, p = 0.04). The inhibition levels of
p-Src, p-Akt and p-FAK were measured when cells were treated with



































*  * *
Figure 7 Effect of dasatinib on PLC/PRF/6 cell signaling. Total
Src and p-Src, p-EGFR expression after dasatinib treatment in PLC/
PRF/6 cell line were shown. P-Src/t-Src was quantified by ImageJ
software. * p < 0.05 as compared with the control (student’s t-test).
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sk-Hep1 cells [11].
Dasatinib affects adhesion, migration and invasion of
HCC cells
There was a strong correlation between the p-FAK inhib-
ition and cell adhesion, migration and invasion. After 24 h
pretreatment, dasatinib significantly reduced adhesion of
both sk-Hep1(p < 0.01) and PLC/PRF/6 (p < 0.001) on
various ECM proteins (collagen I, collagen II, collagen IV,
fibronectin, laminin, tenascin, vitronectin) with the range
of inhibition from 25% to 82%, and the reduction percent-
ages by dasatinib showed a similar pattern on both cell
lines. However, in the most resistant cell line, Huh-7, the
adhesion was significantly increased from 13% to 50% by
dasatinib at the dose of 1uM (Figure 9, p < 0.01).
Dasatinib significantly reduced sk-Hep1 cells migration
6 h after removal from media (70% reduction as compared
to control) (p < 0.001) but the inhibition of migration at
16 h was only 20% (Figure 10B). However, it reducedPLC/PRF/6 migration by 71% significantly at 16 h
(p < 0.001). Again, Huh-7 cells migration was increased
50% by dasatinib (p < 0.001) (Figure 10A).
Dasatinib significantly inhibited the invasion on ECM
in sk-Hep1 cells (Figure 11, p < 0.001). Our results did
not show any invasion inhibition by dasatinib in PLC/
PRF/6 and Huh-7, however, PLC/PRF/6 and huh-7 were
not invasive even in the absence of dasatinib.
Discussion
In this report, we first demonstrated the heterogeneous
sensitivity of 9 HCC cell lines to dasatinib in vitro as
shown by their IC50 values. Our study also showed that
the growth inhibition by dasatinib was correlated with t-
Src in 7/9 cell lines and the p-Src/t-Src ratios were signifi-
cantly lower in sensitive cells than resistant cells in the
same 7/9 cell lines. In 6 resistant cell lines the growth in-
hibition by dasatinib was related to specific activity of Src
protein by p-Src/t-Src ratio. With the exception of PLC/
















































































































Figure 8 The effect of EGF stimulation on phosphorylated protein expression. PLC/PRF/6 cells were stimulated with 10 ng/ml EGF for the
indicated times, lysed and analyzed by western blotting (A). Sk-Hep1 cells were stimulated with 200 ng/ml EGF for the indicated times, lysed and
analyzed by western bloting with the indicated antibodies (C). The expression ratio of phosphorylated protein to β-actin was quantified by
ImageJ software respectively. Results represented the mean (±SD) of three experiments. * p < 0.05 as compared with the control (student’s t-test)
(B and D).
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resulted in apoptosis in gefitinib-sensitive EGFR mutant
lung cancer cells in-vitro [21]. Their findings were also
confirmed by other investigators recently [23,24]. Our re-
sults showed even in gefitinib resistant HCC cell lines
[22], some were still sensitive to dasatinib. There was also
a co-overexpression with Src and members of EGFR fam-
ily in breast cancer [25]. Our findings that EGFR expres-
sion influenced the response of HCC cells to dasatinib
further strengthened the notion that a unique cross-talk
mechanism might exist between Src family and EGFR
family tyrosine kinases in hepatocarcinogenesis. These
two TK signaling pathways may complement each other
in the oncogenic process and development of resistance to
treatment of either pathway. Our results suggested com-
bination of inhibitors of both pathways may yield better
results, as we have shown synergistic interaction between
dasatinib and gefitinib in HCC cells on our previous study
[22]. The preliminary study of dasatinib and erlotinib (an
EGFR TKI) combination in 29 evaluable patients with re-
current or metastatic non-small cell lung cancer showed 2
partial response and 62% disease control rate [26]. More
studies are needed to explore the optimal combination
and the right clinical settings.
Baseline t-Src and specific Src activity (p-Src/t-Src) may
be used as useful predictive biomarkers for selecting
dasatinib treatment in HCC patients. We also showed in
most of cell lines, dasatinib suppressed the expression of
p-Src, p-FAK and p-Akt which correlated with the level of
growth inhibition. So the inhibitory response of p-Src, p-FAK and p-Akt to dasatinib may also provide guidance for
predicting response, although they were more variable
than baseline t-Src. Significant correlation between IC50
and expression of t-Src could be shown in majorities of
cell lines, especially in gefitinib resistant cell lines. How-
ever, there were exceptions, such as Huh-7 cells, Src-
dependant signal pathway was not an important determin-
ant of cell proliferation, motility and invasion in Huh-7
cells which was resistant to dasatinib but showed p-Src in-
hibition by dasatinib. Interestingly, we found that high ra-
tio of p-Src/t-Src was significantly associated with less
resistant to dasatinib in all 6 dasatinib resistant cell lines.
This implied that the mechanism of action of dasatinib in
sensitive cell lines may be different from that of resistant
cell lines. In addition, there were differences among other
cell lines in the inhibition of p-Src, p-FAK, p-Akt, cell ad-
hesion, migration and invasion by dasatinib. Thus, we
demonstrated the heterogeneity of HCC tumor biology
and the need for individualized treatment. Biomarkers
may provide guidance for selecting right treatment for the
right patient. It will require prospective studies to validate
our findings. In the study of combination of dasatinib and
erlotinib in patients with advanced NSCLC, reduction of
vascular endothelial growth factor (VEGF) was correlated
with disease control [26]. However, a phase II study of sin-
gle agent dasatinib in advanced NSCLC showed that nei-
ther activation of SFK nor EGFR and Kras mutations in
tumor tissue predicted response to dasatinib [27]. No clin-
ical results are available yet from studying dasatinib in ad-
vanced HCC patients.
Col I: Collagen I 
Col II: Collagen II 





















































Figure 9 The effect of dasatinib on cell adhesion in HCC cell
lines (A, B, C). Pretreatment for 24 hours, dasatinib inhibited
adhesion of sk-Hep1 and PLC/PRF/6 cells on ECM protein (A, B), but
increased the adhesion of Huh-7 cells (C). ** p < 0.01 as compared
with the control (student’s t-test).
A
B
Figure 10 The effect of dasatinib on cell migration in HCC cell
lines. A, dasatinib pre-treatment for 24 hours inhibited migration of
sk-Hep1, PLC/PRF/6, but increased migration of Huh-7 cells. B, same
test method as A, dasatinib inhibition on sk-hep1 cells 6 h and 16 h
after removing dasatinib from media. The inhibitory effect was
stronger at 6 h than that at 16 h. ** p < 0.01 and *** p < 0.001 as
compared with the control (student’s t-test).
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migration and invasion. Upon intergrin engagement or
stimulation of EGF or PDGF receptors, FAK autophospho-
rylates at pTyr397, creating a high affinity binding site for
Src, the association between Src and FAK resulted in acti-
vation of Src and phosphorylation of FAK at Tyr 576, 577,
861 and 925. The Src/FAK complex phosphorylated anumber of other focal adhesion proteins and activated
other intra cellular signaling pathway [28]. This interaction
between Src and FAK has been shown to control both cell
motility and invasion [11]. Regarding our results, in 56%
(5/9) studied HCC cell lines, dasatinib inhibits the activity
of Src to reduce phosphorylation of FAK. Inhibition of
FAK at Tyr576/577 was strongly correlated with HCC cell
adhesion, migration and invasion. For 78% (7/9) of studied
HCC cell lines, reduction of activated FAK576/577 was
significantly correlated with the dasatinib sensitivity. Thus
the SFK/FAK signaling pathway plays an important role in
cell adhesion, migration and invasion. Inhibition of this
pathway is one of the mechanisms of action of dasatinib.
In MDA-MB-231 human metastatic breast cells, dasatinib
also showed the inhibition of cell proliferation, migration





















Figure 11 Effect of dasatinib on cell invasion. Invasive Sk-Hep1 HCC cells were captured in the polycarbonate membrane without (A) and
with (B) the treatment of dasatinib at 1uM. Images were taken under invert light microscope (magnification: 100×). Images (C) and (D) were
captured under high-power microscope (magnification: 600×). The cell numbers of at least 6 fields in each image were counted under
microscope (magnification: 200×). The percentages of cell invasion were calculated (E). 3 independent experiments were carried out in duplicate.
*** p < 0.001 as compared with the control (student’s t-test).
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http://www.biomedcentral.com/1471-2407/13/267paxillin, caveolin-1 and p130Cas activation [29]. Fur-
thermore, conditional expression of SrcDN in MCF7 hu-
man breast cancer cells reduces adhesion, migration and
spreading. Because expression of SrcDN alters the shape
of MCF7 cells, immunofluorescence confocal analyses
showed concentrated focal adhesion proteins. However,
the adhesion of cells was reduced [30]. In contrast, the
most resistant HCC cell line Huh-7 expresses escalated
levels of activated FAK576/577 and increases cell adhesion
and migration after dasatinib treatment. A previous study
reported that increased cell adhesion, migration occured at
the same time upon treatment with prostaglandin E2by
mediating FAK/paxillin/Erk2 signal pathway in the same
HCC cell line (Huh-7) [31]. The mechanism of dasatinib
induced increases of cell adhesion, migration in Huh-7
cells need further investigation. However, the nature of cell
origin may determine specific cellular responses and the
activated FAK576/577 may be the factor contributing to
drug resistance.
Our study also revealed that FAK can be activated by
EGF in HCC cell lines. In PLC/PRF/6 cell line, Src andFAK can be activated simultaneously by EGF, and com-
pletely inhibited by dasatinib. In view of this result,
dasatinib may directly inhibit the complete activation of
FAK through reducing the activity of Src TK. For sk-Hep1
cell line, EGF could not activate Src, but dasatinib could
also reduce the activity of FAK, indicating dasatinib may
interplay with other molecules to block the phosphoryl-
ation of FAK, and therefore inhibit the motility and inva-
sion of HCC cells.
The activated PI3K/PTEN/Akt/mTOR pathway has
emerged as a novel contributor to HCC tumor develop-
ment [12]. 56% (5/9) of our studied HCC cell lines showed
the inhibition of Src activity by dasatinib also induced in-
hibition of p-Akt. It suggested that activated Src might
trigger PI3K pathway to activate Akt, which regulated
multiple cellular proteins in cell proliferation, apoptosis,
metastasis and angiogenesis. In PLC/PRF/6 cell line,
complete inhibition of activated Src by dasatinib at the
dosage of 0.1 uM, not only induced the inhibition of Akt
activity at the same dosage, but also induced the inhibition
of p-EGFR at Tyr1068 at higher dosage of 10uM (Figure 6).
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of dasatinib or an indirect target secondary to Src inhib-
ition [8,11].
Our data showed little inhibition of p-Stat3, and p-
MAKP 42/44 by dasatinib in all HCC cell lines except at
high concentration. Activation of Stat3 by altered Janus-
activated Kinase-Stat3 binding has been reported as a po-
tential mechanism of resistance to Src inhibition [32] and
should be a focus of future research on mechanisms of
dasatinib resistance. In the resistant Huh-7 cells, p-Stat3
expression was not different from sensitive cell lines,
suggesting Stat3 may not play an important role in this
cell line. Dasatinib was synergistic with oxaliplatin against
colon carcinoma cells and with cisplatin against NSCLC
cells [33,34]. It was also synergistic with gefitinib, bravinib,
BMS-690514, BMS-536924 or ixabepilone as shown in
our previous studies [22]. In the future, it may be neces-
sary to perform genomic and proteomic evaluation of each
patient to determine resistance patterns as shown by
Li et al. that dasatinib had nearly 40 distinct kinase targets
[35,36].
Conclusions
Dasatinib inhibits the proliferation, adhesion, migration
and invasion of HCC cells in vitro via inhibiting Src and
affecting SFK/FAK and PI3K/PTEN/Akt signaling path-
ways, but not Ras/Raf/MEK/ERK and JAK/Stats pathways.
Apart from Src, dasatinib may also inhibit other tyrosine
kinase protein or growth factor receptors in HCC cells. In
general the growth inhibition by dasatinib was related t-
Src and the ratio of p-Src/t-Src. T-Src and p-Src/t-Src may
be useful biomarkers to select HCC patients for dasatinib
treatment in the future. This is consistent with the notion
that the Src family Kinases cooperate with multiple recep-
tor tyrosine Kinases to modulate signaling cross talk and
promoting proliferation, adhesion, migration and invasion.
Furthermore, dasatinib could be an attractive agent for
combination therapies such as combining with EGFR TKI
or chemotherapy to exploit potential synergistic inter-
action. Hence, further laboratory and translational re-
searches are warranted to investigate the role of dasatinib
or other Src inhibitor in HCC.
Additional file
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(student’s t-test).
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